These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
540 related articles for article (PubMed ID: 30155893)
1. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer. Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893 [TBL] [Abstract][Full Text] [Related]
2. Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study. Hermans TJ; Fransen van de Putte EE; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; de Wit R; Beerepoot LV; Verhoeven RH; van Rhijn BW Eur J Cancer; 2016 Dec; 69():1-8. PubMed ID: 27814469 [TBL] [Abstract][Full Text] [Related]
3. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients. van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294 [TBL] [Abstract][Full Text] [Related]
4. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. Faiena I; Salmasi A; Mendhiratta N; Lenis AT; Pooli A; Drakaki A; Gollapudi K; Blumberg J; Pantuck AJ; Chamie K World J Urol; 2018 Nov; 36(11):1825-1833. PubMed ID: 29752514 [TBL] [Abstract][Full Text] [Related]
5. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone. Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy. Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W; J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894 [TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Li R; Nocera L; Rose KM; Raggi D; Naidu S; Mercinelli C; Cigliola A; Tateo V; Patanè D; Grass GD; Gilbert SM; Sexton WJ; Bandini M; Moschini M; Briganti A; Montorsi F; Spiess PE; Necchi A Eur Urol Oncol; 2024 Jun; 7(3):614-624. PubMed ID: 38184473 [TBL] [Abstract][Full Text] [Related]
8. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841 [TBL] [Abstract][Full Text] [Related]
9. Perioperative treatment and radical cystectomy for bladder cancer--a population based trend analysis of 10,338 patients in the Netherlands. Hermans TJN; Fransen van de Putte EE; Horenblas S; Lemmens V; Aben K; van der Heijden MS; Beerepoot LV; Verhoeven RH; van Rhijn BWG Eur J Cancer; 2016 Feb; 54():18-26. PubMed ID: 26707593 [TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder. Fischer-Valuck BW; Rao YJ; Henke LE; Rudra S; Hui C; Baumann BC; Gay HA; Michalski JM Eur Urol Focus; 2018 Dec; 4(6):900-906. PubMed ID: 28919521 [TBL] [Abstract][Full Text] [Related]
11. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503 [TBL] [Abstract][Full Text] [Related]
12. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. Parker WP; Ho PL; Boorjian SA; Melquist JJ; Thapa P; Holzbeierlein JM; Frank I; Kamat AM; Lee EK World J Urol; 2016 Nov; 34(11):1561-1566. PubMed ID: 26943643 [TBL] [Abstract][Full Text] [Related]
13. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y; Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010 [TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder. Minato A; Noguchi H; Tomisaki I; Fukuda A; Kubo T; Nakayama T; Fujimoto N Cancer Control; 2018; 25(1):1073274818800269. PubMed ID: 30213195 [TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254 [TBL] [Abstract][Full Text] [Related]
16. Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. Mitra AP; Cai J; Miranda G; Bhanvadia S; Quinn DI; Schuckman AK; Djaladat H; Daneshmand S J Urol; 2022 Feb; 207(2):302-313. PubMed ID: 34994657 [TBL] [Abstract][Full Text] [Related]
17. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837 [TBL] [Abstract][Full Text] [Related]
18. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. Soria F; Black PC; Fairey AS; Cookson MS; Yu EY; Kassouf W; Dall'Era MA; Sridhar SS; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Daneshmand S; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Shariat SF; Gontero P BJU Int; 2021 Jul; 128(1):79-87. PubMed ID: 33152179 [TBL] [Abstract][Full Text] [Related]
20. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. von Landenberg N; Speed JM; Cole AP; Seisen T; Lipsitz SR; Gild P; Menon M; Kibel AS; Roghmann F; Noldus J; Sun M; Trinh QD Urol Oncol; 2018 Feb; 36(2):78.e13-78.e19. PubMed ID: 29169845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]